Focus: Zevra Therapeutics is a publicly traded biotech company focused on rare diseases through modification of existing drugs. The company operates from Denmark with a lean, specialized commercial footprint.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
4 added, 3 removed. Backfill posture.
Zevra offers rare-disease focus and commercial stability for specialists seeking specialty pharma experience, but limited growth scale for generalists seeking rapid advancement.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole approved product generating revenue; extended LOE through 2031 provides multi-year commercial runway.
Help build intelligence for Zevra Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zevra Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Zevra Therapeutics to Present New Long-Term Real-World Data - GlobeNewswire
Zevra Therapeutics to Present New Long-Term Real-World Data GlobeNewswire
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Zevra Therapeutics (ZVRA) insider sells 42,666 shares Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position Stock Titan
Zevra Therapeutics faces investigation after EM... - Pluang
Zevra Therapeutics faces investigation after EM... Pluang
Zevra Therapeutics, Inc. (ZVRA) stock price, news, quote and history - Yahoo Finance Australia
Zevra Therapeutics, Inc. (ZVRA) stock price, news, quote and history Yahoo Finance Australia
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation ACCESS Newswire
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy.
Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial.
Showing 5 of 7 publications